DSIP
Overview
Mechanisms
Evidence
[regulatory]US status shifting (2026): DSIP (nominated as Emideltide) was removed from FDA Category 2 (Feb 2026) and is on the FDA PCAC 503A agenda for July 24 2026 — FDA’s evaluated uses are opioid withdrawal, chronic insomnia, and narcolepsy. Advisory/non-binding; not FDA-approved. — SOURCE-fda-pcac-503a-peptide-review-2026